Lille (France), Cambridge (Mass.), March 27, 2008 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111) the biopharmaceutical company at the forefront of research and development of cardiovascular, inflammatory and metabolic drugs today announced encouraging clinical results for activity and tolerance of GFT505 in patients presenting mixed dyslipidemia of type 2b (Triglycerides > 200 mg/dL and LDL-C>130 mg/dL). General tolerance is excellent, and no serious adverse effect was recorded. Dyslipidemia is thought to affect between 4 and 10% inclusive of the world population... [PDF] GENFIT's Press Release - PDF du Communiqué de Presse GENFIT -
Friday, April 25, 2008
GENFIT : encouraging results in GFT505 first clinical trial of efficacy
Lille (France), Cambridge (Mass.), March 27, 2008 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111) the biopharmaceutical company at the forefront of research and development of cardiovascular, inflammatory and metabolic drugs today announced encouraging clinical results for activity and tolerance of GFT505 in patients presenting mixed dyslipidemia of type 2b (Triglycerides > 200 mg/dL and LDL-C>130 mg/dL). General tolerance is excellent, and no serious adverse effect was recorded. Dyslipidemia is thought to affect between 4 and 10% inclusive of the world population... [PDF] GENFIT's Press Release - PDF du Communiqué de Presse GENFIT -
